CIK 0001740279
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
IN8BIO, INC.
Sign in to watch- Ticker
- INAB
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 825462585
- Phone
- +1 646-600-6438
- Business address
- EMPIRE STATE BUILDING, 350 5TH AVENUE, SUITE 5330, NEW YORK, NY, 10118
- Former names
- Incysus Therapeutics, Inc.
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 4 Conversion 10% owner acquired 6,625,102 shares (conversion)
- 4 Conversion President, CEO and CFO acquired 3,070 shares (conversion)
- 4 Conversion 10% owner acquired 6,625,102 shares (conversion)
- 4 Open-market buy Director bought 100,000 shares at $10.00 ($1,000,000)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
Page 9 of 10 · 185 filings